$TWST

Green Paula sold $25K of TWST

Green Paula (SVP of Human Resources) sold 291 shares of Twist Bioscience Corp (TWST) at $87.32 on 2026-06-22.

Original reporting
SEC EDGAR · Green Paula
Published Jun 24, 2026, 8:05 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Jun 24, 2026, 8:10 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
alphai market briefInsider activity
Primary signal
$TWST
Neutral
medium confidence
Mentioned
$TWST
Relevance
3/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$TWSTNeutralLow
01

Why it matters

This provides a fresh datapoint on insider behavior but does not include guidance, operational updates, or legal/financial events.

02

Market read

Traders may monitor for follow-on insider activity, but the disclosed sale is small and not tied to a corporate catalyst.

03

What to watch

No 10b5-1 plan is indicated, but the filing does not provide intent or context; traders should avoid extrapolating from a single small sale.

Relevance 3/10Novelty 3/10Timing: Filed 2026-06-24 after-hours; reflects sale executed 2026-06-22.

Background

The article is a primary-source SEC Form 4 insider transaction disclosure for Twist Bioscience.

Company-level read

Ticker impact

$TWSTNeutralMedium confidence
Context

Twist Bioscience disclosed an SVP of Human Resources open-market sale of 291 shares at $87.3224 on 2026-06-22 via Form 4.

Expected impact

Low likelihood of a sustained price move; any impact is likely short-lived and sentiment-driven.

Evidence & confidence

The filing is a small, single-tranche open-market sale by an HR SVP with no 10b5-1 plan stated; size is modest ($25.4k) and does not indicate a corporate event.

Market effects

Minimal; this is company-specific insider activity with no sector-wide catalyst.

None expected beyond normal US small-cap/biotech sentiment noise.

None expected.

Counterpoint

The sale may be purely personal liquidity (e.g., taxes/financial planning) and not a view on fundamentals, especially given the modest dollar amount.

Key entities

  • Twist Bioscience Corp

    Subject of the Form 4 insider transaction disclosure.

  • Green Paula

    SVP of Human Resources who sold 291 shares in an open-market transaction.

Related articles

$TWSTMedAI 8/10

Twist Announces Pricing Of $300 Mln Underwritten Upsized Public Offering

Twist Bioscience (TWST) priced an underwritten upsized public offering of 3.12 million shares at $96.00 each, raising about $300 million in gross proceeds. Underwriters received a 30-day option for up to an additional $37.5 million. Proceeds will fund R&D, manufacturing expansion, working capital and general purposes. Closing is expected Aug. 6, 2026.

$TWSTMed

Twist Bioscience Q3 Earnings Call Highlights

Twist Bioscience (NASDAQ:TWST) reported Q3 revenue of about $77.3M in the Americas (+30% YoY), $33.6M in EMEA (+9%), and $7.5M in APAC (+26%). Global supply partner revenue was $12.9M. Gross margin was 52.8%. It raised FY2026 revenue guidance to $456M-$457M and forecast Q4 revenue of $123M-$124M.

$TWSTMed

Why is Twist Bioscience stock sliding today?

Twist Bioscience shares (TWST) fell 4.2% in pre-open after its fiscal Q3 results missed EPS expectations. The company reported an EPS loss of $0.56 versus $0.48 expected, while revenue was $118.4M, above the $114.54M estimate. The miss follows similar EPS shortfalls in prior quarters, with mixed analyst actions noted.

$TWSTHigh

Twist Bioscience Corp (TWST): Results of Operations and Financial Condition

Twist Bioscience Corp (TWST) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 twst-2026630xex991.htm EX-99.1 Document Exhibit 99.1 Twist Bioscience Reports Fiscal Third Quarter 2026 Financial Results — Record revenue of $118.4 million in 3QFY26 ; Increase of more than 23% over $96.1 million in 3QFY25; 14th consecutive quarter of sequential growth

$AMDMedAI 8/10

Cathie Wood Pours $8. 5M Into Cerebras Amid Buzz Around AI Chip Upstart, Wont Stop Dumping AMD - Advanced

According to Benzinga, Cathie Wood’s Ark made a $10.8M purchase of Cerebras shares (42,126) on Friday, while also selling 16,998 shares of Teradyne and buying 2,451 shares of Twist Bioscience via ARKK. Separately, the report notes AMD is ramping Vera Rubin production, but U.S.-China policy and China’s share of net sales remain key factors for investors.